Trials / Withdrawn
WithdrawnNCT03027934
A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- CirQuest Labs, LLC · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in a cross-over design.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticagrelor | Ticagrelor, 90mg twice daily |
| DRUG | Prasugrel | Prasurgrel, 10mg once daily |
Timeline
- Start date
- 2017-08-28
- Primary completion
- 2017-10-31
- Completion
- 2017-10-31
- First posted
- 2017-01-23
- Last updated
- 2020-07-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03027934. Inclusion in this directory is not an endorsement.